• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.

作者信息

Unsworth-White Samantha, Humayun-Zakaria Nada, Bryan Richard T

机构信息

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

出版信息

Transl Androl Urol. 2025 Jan 31;14(1):1-3. doi: 10.21037/tau-24-529. Epub 2025 Jan 16.

DOI:10.21037/tau-24-529
PMID:39974809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11833534/
Abstract
摘要

相似文献

1
Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.卡介苗无反应性高危非肌层浸润性膀胱癌患者治疗中风险与获益的平衡
Transl Androl Urol. 2025 Jan 31;14(1):1-3. doi: 10.21037/tau-24-529. Epub 2025 Jan 16.
2
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验：SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
3
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.阿特珠单抗单药或联合卡介苗用于高危非肌肉浸润性膀胱癌患者的 1b/2 期研究。
Eur Urol Oncol. 2023 Jun;6(3):313-320. doi: 10.1016/j.euo.2023.01.013. Epub 2023 Feb 15.
4
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.吉西他滨和多西他赛序贯膀胱内灌注与卡介苗治疗卡介苗无反应性非肌层浸润性膀胱癌患者的肿瘤学结局比较
Eur Urol Oncol. 2025 Apr;8(2):469-476. doi: 10.1016/j.euo.2024.12.005. Epub 2024 Dec 17.
5
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.卡介苗无反应性非肌层浸润性膀胱癌患者的膀胱保留治疗：长期生存结果分析
Eur Urol Open Sci. 2023 May 13;53:16-22. doi: 10.1016/j.euros.2023.04.013. eCollection 2023 Jul.
6
Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.免疫疗法在卡介苗无反应性非肌肉浸润性膀胱癌中的作用
Transl Cancer Res. 2020 Oct;9(10):6537-6545. doi: 10.21037/tcr-20-758.
7
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.CREST 研究：sasanlimab 联合卡介苗治疗卡介苗初治高危非肌层浸润性膀胱癌患者的 III 期临床研究。
Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8.
8
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
9
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.经卡介苗膀胱内灌注后非肌层浸润性膀胱癌的膀胱保留治疗疗效的系统评价
Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4.
10
Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.阿替利珠单抗在卡介苗无反应的高危非肌层浸润性膀胱癌中的应用。
Transl Androl Urol. 2024 Jun 30;13(6):1061-1063. doi: 10.21037/tau-23-630. Epub 2024 May 24.

本文引用的文献

1
Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.阿替利珠单抗在卡介苗无反应的高危非肌层浸润性膀胱癌中的应用。
Transl Androl Urol. 2024 Jun 30;13(6):1061-1063. doi: 10.21037/tau-23-630. Epub 2024 May 24.
2
Circulating Tumour DNA Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.通过对肌肉浸润性膀胱癌患者存档血清样本进行尿液信息分析来检测循环肿瘤DNA
Eur Urol. 2024 May;85(5):508-509. doi: 10.1016/j.eururo.2024.01.016. Epub 2024 Feb 1.
3
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
atezolizumab 在卡介苗无应答高危非肌肉浸润性膀胱癌中的 2 期临床试验：SWOG S1605。
Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.
4
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.派姆单抗膀胱内给药治疗复发性非肌层浸润性膀胱癌的1期研究
BJUI Compass. 2023 Jan 13;4(3):322-330. doi: 10.1002/bco2.220. eCollection 2023 May.
5
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.阿特珠单抗单药或联合卡介苗用于高危非肌肉浸润性膀胱癌患者的 1b/2 期研究。
Eur Urol Oncol. 2023 Jun;6(3):313-320. doi: 10.1016/j.euo.2023.01.013. Epub 2023 Feb 15.
6
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.度伐利尤单抗联合卡介苗（BCG）或外照射放疗用于卡介苗无反应性非肌层浸润性膀胱癌患者的1期试验：印第安纳癌症研究网络GU16 - 243 ADAPT - 膀胱研究。
Eur Urol. 2023 Jun;83(6):486-494. doi: 10.1016/j.eururo.2023.01.017. Epub 2023 Jan 28.
7
Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.新型膀胱内治疗药物在非肌层浸润性膀胱癌治疗中的应用：前沿扫描
Front Surg. 2022 Jul 26;9:912438. doi: 10.3389/fsurg.2022.912438. eCollection 2022.
8
Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes.非肌肉浸润性膀胱癌的外显子组和转录组联合测序：基因组改变、表达亚型与临床结局之间的关联。
Genome Med. 2022 Jun 3;14(1):59. doi: 10.1186/s13073-022-01056-4.
9
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.机器人辅助根治性膀胱切除术与体外尿路分流术对比开放性根治性膀胱切除术对膀胱癌患者 90 天内发病率和死亡率的影响：一项随机临床试验。
JAMA. 2022 Jun 7;327(21):2092-2103. doi: 10.1001/jama.2022.7393.
10
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.ctDNA 指导尿路上皮癌的辅助免疫治疗。
Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16.